Airna will use the Series B round to launch a Phase 1/2 trial of its lead program for alpha-1 antitrypsin deficiency, a ...

Strengthens leadership team with additional key appointment of GaoZhong Zhu, Ph.D. as Senior Vice President of Chemistry, Manufacturing and Controls (CMC) & Technical Operations and promotion of ...

Korro Bio's OPERA platform offers precise RNA editing for genetic diseases like Alpha-1 antitrypsin deficiency. Learn more on ...

In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Korro Bio (KRRO – Research Report), with a price ...

Korro Bio (NASDAQ:KRRO – Free Report) had its target price cut by Royal Bank of Canada from $105.00 to $95.00 in a research report sent to investors on Wednesday morning,Benzinga reports. They ...

Shares of Korro Bio, Inc. (NASDAQ:KRRO – Get Free Report) have been assigned a consensus rating of “Buy” from the seven ...

RBC Capital lowered the firm’s price target on Korro Bio (KRRO) to $95 from $105 and keeps an Outperform rating on the shares. The firm notes ...

So, the natural question for Korro Bio (NASDAQ:KRRO) shareholders is whether they should be concerned by its rate of cash burn. In this article, we define cash burn as its annual (negative) free cash ...

March 18, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for ...

March 18, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA ...

Korro Bio completed dosing for its KRRO-110 study in AATD, expects interim results in 2025, and has strong financial resources. Korro Bio, Inc. has completed dosing for the first two cohorts in ...

March 18, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA ...